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Rationale—The majority of current cardiovascular cell-therapy trials use bone marrow 
progenitor cells (BM PCs) and achieve only modest efficacy; the limited potential of these cells to 
differentiate into endothelial-lineage cells is one of the major barriers to the success of this 
promising therapy. We have previously reported that the E2F transcription factor 1 (E2F1) is a 
repressor of neovascularization following ischemic injury.
Objective—We sought to define the role of E2F1 in the regulation of BM PC function.
Methods and Results—Ablation of E2F1 (E2F1−/−) in mouse BM PCs increases oxidative 
metabolism and reduces lactate production, resulting in enhanced endothelial differentiation. The 
metabolic switch in E2F1−/− BM PCs is mediated by a reduction in the expression of pyruvate 
dehydrogenase kinase 4 (PDK4) and PDK2; overexpression of PDK4 reverses the enhancement of 
oxidative metabolism and endothelial differentiation. Deletion of E2F1 in the BM increases the 
amount of PC-derived endothelial cells in the ischemic myocardium, enhances vascular growth, 
reduces infarct size, and improves cardiac function after myocardial infarction.
Conclusion—Our results suggest a novel mechanism by which E2F1 mediates the metabolic 
control of BM PC differentiation, and strategies that inhibit E2F1 and/or enhance oxidative 
metabolism in BM PCs may improve the effectiveness of cell therapy.
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INTRODUCTION
The majority of current clinical trials for cardiovascular cell therapy use BM PCs 1, because 
they are well characterized and include a subpopulation of endothelial PCs (EPCs), which 
play a crucial role in cardiovascular homeostasis 2. However, despite ample evidence from 
the literature indicating that the transplanted cells are incorporated into the vasculature and 
secrete angiogenic growth factors that support the developing microvasculature 3, 4, the 
clinical efficacy observed in these trials remains modest 1; very few of the transplanted (or 
mobilized endogenous) PCs differentiate into vascular cells to achieve functional integration 
and long-term engraftment, and this limited potential for differentiation into endothelial-
lineage cells is one of the major barriers to the success of PC therapy 5.
Ischemic injury induces a variety of mechanisms that promote angiogenesis in the injured 
tissue. This angiogenic environment should, at least in theory, induce the differentiation of 
PCs into vascular ECs, but very few recruited PCs actually become incorporated into the 
vasculature and display a true EC phenotype 6. It is known that undifferentiated PCs are 
relatively quiescent, relying primarily on anaerobic glycolysis for energy production 7; 
activation (and subsequent differentiation) of the quiescent cells is often accompanied by a 
metabolic change or “switch” from anaerobic glycolysis to mitochondrial oxidative 
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phosphorylation (mtOP) 8. Interestingly, recent reports suggest that this metabolic switch is 
largely controlled by pyruvate dehydrogenase kinases 4 and 2 (PKD4/2) 9. PDK4/2 
phosphorylate pyruvate dehydrogenase (PDH), which inactivates the PDH complex, and this 
decline in PDH complex activity limits mtOP 10–12. Intriguingly, when the PDK4/2 genes 
are deleted in hematopoietic stem cells (HSCs), the HSCs are forced to switch from 
anaerobic glycolysis to mtOP, and this change is associated with a marked increase in the 
number of mature blood cells and decline in the number of HSCs 9; conversely, when mtOP 
is disrupted by deleting the mitochondrial phosphatase PTPMT1, HSC differentiation is 
blocked, the number of mature blood cells declines, and HSC numbers increase by ~40-fold 
13
. These provocative findings encourage us to hypothesize that the failure of BM PCs to 
assume an EC identity occurs because these cells are not metabolically primed for 
differentiation; i.e., the cells continue to produce energy primarily through anaerobic 
glycolysis, which supports quiescence, rather than mtOP, which is required for 
differentiation, and that priming the metabolic switch in BM PCs at the site of vascular 
injury may enhance the differentiation of PCs into endothelial-lineage cells and promote 
cardiovascular repair.
E2F1 is a member of the E2F family transcription factors known for regulating cell 
proliferation and apoptosis 14. However, evidence from our lab and others suggests that 
E2F1 is dispensable for vascular growth; rather, loss of E2F1 in mice is protective during 
ischemic and ischemic reperfusion injuries 15–17. Interestingly, E2F1 has recently been 
recognized as a major regulator of energy metabolism. In skeletal muscle and adipose 
tissues, E2F1 suppresses the expression of components in the mitochondrial respiratory 
chain, and E2F1-deficient (E2F1−/−) mice display elevated exercise endurance and resistance 
to cold-induced hypothermia 18. Intriguingly, E2F1 has also been shown to bind to PDK4 
promoter and activate PDK4 expression in myoblasts 19. However, it is unknown whether 
E2F1 regulates the metabolism and differentiation of BM PCs and whether this regulation is 
attributable to the beneficial effect of E2F1 deficiency under ischemic injury.
Here we report that in BM PCs, E2F1 is a potent activator of PDK4/2 gene expression; 
genetic deletion of E2F1 leads to decreased PDK4/2 expression, increased oxidative 
metabolism and endothelial differentiation, and enhanced vascular repair after MI. Thus 
reset of BM PC metabolism via inhibition of E2F1 and/or enhancement of mtOP may 
provide a novel strategy for enhancing the effectiveness of cell therapy.
METHODS
All materials, methods, and supporting data are available within the article and the online 
supplementary file.
Mice
The E2F1−/− and Tie2/LacZ mice were obtained and genotyped as we reported previously 
16, 17
. Age-matched male mice were used. Sample sizes were determined by power 
calculation with 80% power. The investigators responsible for histological analyses were 
blinded to surgical groups. Mice were randomly assigned to the experimental groups. All 
animals were bred, maintained, and operated in the Center for Comparative Medicine of 
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Northwestern University and the Animal Resources Program of the University of Alabama 
at Birmingham following protocols approved by the Institutional Animal Care and Use 
Committees.
Isolation and culture of BM PCs
BM mononuclear cells (MNCs) were isolated by density gradient centrifugation 20. Lineage-
negative (Lin−) PCs were enriched through a lineage cell depletion kit, followed by an 
additional step to deplete CD31+ cells (Miltenyi Biotec, Cambridge, MA); the final purity 
(>95%) and amount of CD31+ cells (<0.2%) were confirmed by flow cytometry. The Lin− 
PCs were either used freshly or maintained in suspension culture with IMDM plus 10% 
FBS, thrombopoietin (20 ng/mL), stem cell factor (10 ng/mL), and IL-3 (6 ng/mL) (R & D 
Systems) as we previously described 20.
Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) measurements
OCR and ECAR of BM PCs were measured with Seahorse XF24 extracellular flux analyzer 
(Seahorse Bioscience). Briefly, Lin− BM PCs were seeded in 100 μL culture medium at a 
density of 5 × 105/well in XF24 24-well cell culture plate coated with BD Cell-Tak (BD 
Biosciences) and incubated at 37°C for 30 min. Following cell attachment, an additional 400 
μL medium was added to each well, and incubated at 37°C overnight. Prior to analysis, the 
medium was gently removed and replaced with 500 μL pre-warmed specially formulated 
Seahorse DMEM (Seahorse Bioscience) supplemented with 10 mM glucose (assay medium) 
and incubated at 37°C without CO2 for 1 h. Following calibration of the XF24 sensor 
cartridge, the cell culture plate was placed in the analyzer and the ECAR and OCR were 
simultaneously measured. ECAR and OCR rates were normalized to cell numbers.
In vitro differentiation assay
BM MNCs were cultured on vitronectin-coated flasks in EGM-2 medium supplemented 
with endothelial growth factor cocktail SingleQuots (Clonetics, San Diego, CA) 21. After 4d 
culture, non-adherent cells were removed, and new medium was applied. The adherent cells 
were maintained for a total of 7d before phenotypic and functional assessments.
Quantitative real-time RT-PCR (qRT-PCR)
qRT-PCR was performed as we described previously 20. Primer sequences for genes 
encoding for Atp5g1, Cox5a, Ndufv1, Sdha, Uqcr, Idh3a, Ucp2, PGK, PDK1-4, E2F1-8, and 
β-actin were reported in Online Table I. The results were normalized to the mRNA levels of 
β-actin or 18S.
Western blotting
Proteins were extracted in cell lysis buffer (Cell Signaling Technology) and analyzed with 
Western blotting by using rabbit anti-PDK4 antibody (1:500; Abcam), rabbit anti-PDK2 and 
anti-phospho-PDH antibodies (1:250; Santa Cruz), and rabbit anti-β-actin and anti-α-tubulin 
antibodies (1:3000; Cell Signaling Technology). The intensities of protein bands were 
quantified densitometrically by using the NIH IMAGE software.
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Flow cytometry
BM PC-derived ECs were blocked with mouse Fc blocker, stained with FITC-conjugated 
anti-mouse CD31 and PE-conjugated anti-mouse Flk-1 antibodies (BD Biosciences), and 
analyzed on a FACSCantoII flow cytometer (BD Biosciences), as we described elsewhere 21.
Lentiviral vectors and BM PC transduction
The vector backbone plasmid LeGo-iC2 (control-mCherry) was purchased from Addgene 
(Cambridge, MA). The mouse PDK4 cDNA on pCMV6-PDK4 was purchased from 
OriGene (Rockville, MD) and cloned into LeGo-iC2 to generate LeGo-PDK4 (PDK4-
mCherry) by using the EcoR I and Not I restriction sites. To produce lentiviral vectors, the 
backbone plasmids were co-transfected, separately, with envelope (pMD2.G) and packaging 
(psPAX2) plasmids 22 into 293FT cells; 2d later, virus-containing supernatants were 
collected and concentrated by ultracentrifugation 22. To infect BM PCs, the lentivirus were 
applied to the cells (MOI: 50) with polybrene (8 ug/mL final concentration). The medium 
was replaced on the following day, and the cells were cultured for an additional 3 days 
before FACS sorting for the transduced cells based on mCherry expression.
BM transplantation (BMT)
To evaluate the role of BM E2F1 in the ischemic cardiac repair, BMT was performed to 
reconstitute the BM of lethally-irradiated WT mice with E2F1-knockout/eGFP-transgenic 
(E2F−/−eGFP) or eGPF (control) donor BM-MNCs 21. Eight weeks after BMT, the 
engraftment was assessed by FACS for the proportion of eGFP-expressing peripheral blood 
MNCs cells isolated from ~100 uL tail-bleed. The recipients with an engraftment >90% 
were chosen for surgical induction of MI.
Surgical induction of MI and echocardiography
MI was induced in mice by permanent ligation in the middle of the left anterior descending 
(LAD) coronary artery 23. Trans-thoracic 2-dimensional echocardiographic measurements 
were performed before MI (baseline) and at 7, 14 and 28 days post-MI by using a Vevo 
770TM high-resolution ultrasound biomicroscope (VisualSonics Inc, Toronto, Ontario, 
Canada) and Vevo analysis software (Vevo 2.2.3; VisualSonics Inc) 23. Mice were lightly 
anesthetized with inhaled 2% Isofluorane, and heart rates were maintained at 400 to 500 
beats per minute. M-Mode and B-Mode images were recorded, and left ventricular fractional 
shortening (FS) and ejection fraction (EF) were calculated 23.
Histological assessments
Cardiac tissues were fixed in 4% paraformaldehyde for 4 h, then snap-frozen. Serial 
cryosectioning was performed starting at 1 mm below the suture (used to ligate the LAD) 
moving toward the apex, with three consecutive sections per 1 mm to allow for quantitative 
pathohistological analysis at each level 23. The Masson Trichrome elastic tissue staining was 
performed, and infarct size was reported as the ratio of the length of fibrotic area to the 
length of the LV inner circumference. To evaluate PC endothelial differentiation and 
capillary density, immunohistochemical staining was performed using fluorescent anti-BS 
Lectin 1 (Vector Laboratories, Inc.) and anti-CD31 (Santa Cruz) antibodies 16, 21, 23; 3 
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sections per ischemic heart and 6 fields per section were examined. All surgical procedures 
and pathohistological analyses were performed by investigators blinded to treatment 
assignments.
Statistical analyses
All values are reported as mean ± SEM. Two-tailed Student’s t-test was used to compare two 
means. One-way or two-way analysis of variance (ANOVA) with a Bonferroni correction 
was used to compare multiple (>2) means with one or two independent variables 
respectively. A p-value of <0.05 was considered significant.
RESULTS
E2F1 deficiency increases OCR and decrease ECAR in BM PCs
We firstly isolated Lin− BM PCs from E2F1−/− and WT mice and measured OCR at baseline 
and after sequential treatments with F1F0 ATP synthase inhibitor Oligomycin, uncoupler 
FCCP, and electron-transport-chain blocker Antimycin A plus Rotenone. Compared to WT 
PCs, E2F1−/− PCs displayed a significantly greater OCR; the basal and maximum (FCCP-
induced) OCR in E2F1−/− PCs were elevated by 53.8% and 50.4%, respectively (Figure 1A 
& 1B). Treatment with Oligomycin or with Antimycin A plus Rotenone abrogated the 
differences in OCR between the two groups of cells. In contrast, the ECAR level was 
lowered in E2F1−/− PCs by 73.5% at baseline and by 83.6% with Oligomycin treatment 
(Figure 1C & 1D). We then measured the level of lactate, the end product of anaerobic 
glycolysis, and the activity of glucose-6-phosphate dehydrogenase (G6PDH), a rate-limiting 
enzyme of the pentose phosphate pathway (PPP), in these cells. Consistent with the reduced 
ECAR level, the lactate level was significantly lower in E2F1−/− BM PC than in WT cells 
(Online Figure IA). The G6PDH activities, however, were similar between the two groups of 
cells (Online Figure IB). Thus, endogenous E2F1 expression appears to suppress mtOP and 
promote anaerobic metabolism of pyruvate without altering PPP in BM PCs.
E2F1 deficiency and mtOP elevation promotes the differentiation of BM PCs into 
endothelial-lineage cells
Since increased oxidative metabolism has been linked to PC differentiation, we performed 
an endothelial differentiation assay by culturing same number of E2F1−/− and WT BM PCs 
(CD31+ cell depleted Lin− BM-MNCs) in the differentiation media for 7d. A markedly 
greater proportion (Figure 1E & 1F) and absolute number (Online Figure II) of CD31+, 
Flk-1+, and CD31+Flk-1+ endothelial (lineage) cells were generated from E2F1−/− PCs than 
from WT PCs, though the initial Lin−CD31+ and Lin−Flk-1+ populations were all at low 
level and similar between E2F1−/− and WT BM (Online Figure III and Table II). We then 
isolated CD31+ ECs by FACS and analyzed their function with a tube-formation assay on 
matrigel; there was no difference in the tube-formation activities between E2F1−/− and WT 
ECs (Online Figure IV). In addition, the proliferative capacity, the degree of H2O2-induced 
apoptosis, and chemokine-induced migration were all similar between E2F1−/− and WT PCs 
(Online Figures V & VI).
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To determine whether loss of E2F1 in BM PCs increase their differentiation in vivo, we 
performed experiments in which Lin− BM PCs were isolated from Tie2/LacZ;E2F1−/− or 
Tie2/LacZ (control) mice, depleted of Tie2+ cells, mixed in Matrigel and s.c. implanted into 
WT mice for 5d. This model provided us with the opportunity to quantify endothelial 
differentiation in vivo, defined by the advent of Tie2 driven LacZ expression. Notably, the 
ratio of X-gal+ to total cells was 2 times greater in the Matrigel-plugs containing Tie2-
LacZ;E2F1−/− BM PCs than in the Matrigel-plugs containing Tie2-LacZ BM PCs (Online 
Figure VII), these data further support that loss of E2F1 enhances de novo PC endothelial 
differentiation.
To determine whether the enhanced differentiation capacity of E2F1−/− PCs is mediated by 
the altered metabolic activity, we suppressed mtOP in E2F1−/− and WT BM PCs by adding 
Oligomycin to the differentiation medium. Oligomycin treatment significantly reduced the 
numbers of CD31+ and Flk-1+ E2F1−/− cells to levels that did not differ significantly from 
the numbers of CD31+ and Flk-1+ cells observed in the WT population (Figure 1F). These 
results suggest that the elevation in oxidative metabolism is responsible for the increased 
endothelial differentiation in E2F1−/− PCs. Notably, siRNA-mediated acute knockdown of 
E2F1 in BM PCs also led to a significant increase in mtOP and endothelial differentiation 
(Online Figure VIII), confirming that the observations made in E2F1−/− PCs were not the 
result of developmental adaptation from the knockout mice. Furthermore, the expression 
levels of E2F2–8 were similar between E2F1−/− and WT BM PCs; thus, it is unlikely that 
other E2F members have contributed to the enhanced mtOP and endothelial differentiation 
in E2F1−/− BM PCs (Online Figure IX).
PDK4 and PDK2 are downregulated in E2F1−/− PCs
To identify molecular mechanism by which E2F1 deficiency promotes oxidative metabolism 
and endothelial differentiation, we analyzed WT and E2F1−/− BM PCs for the mRNA 
expression of genes involved in the regulation of glycolysis (Pgk), mitochondria respiration 
(Atp5g1, Cox5a, Ndufv1, Sdha, Uqcr), tricarboxylic acid (TCA) cycle (Idh3a), and 
uncoupling respiration (Ucp2), but found no significant difference between the two groups 
of cells, except Cox5a expression which was about 2-fold greater in E2F1−/− PCs than in 
WT PCs (Figure 2A). Because E2F1 has been shown to bind to PDK promoter and PDKs 
act to limit mtOP by inactivating the PDH complex, we sought to determine whether E2F1 
regulates PDK isoenzymes. While PDK1 and PDK3 expression was similar between the two 
groups of cells, PDK2 and PDK4 mRNA levels were markedly lower in E2F1−/− PCs than in 
WT PCs (Figure 2B). Our chromatin immunoprecipitation (ChIP) assays confirm that E2F1 
occupies the promoter regions of PDK4 and PDK2 that contain the canonical E2F binding 
site, suggesting that E2F1 likely directly regulates PDK4 and PDK2 transcription (Online 
Figure X). Western-blotting analyses confirmed that the protein levels of PDK4 and PDK2 
were markedly reduced in E2F1−/− PCs (Figure 2C & 2D), and so was the level of the 
PDK4/2’s catalytic product, phospho-PDH-E1α (Figure 2C & 2D).
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The enhancement in mtOP and endothelial differentiation in E2F1−/− PCs is mediated by 
the reduced PDK4/2 expression
To determine whether the increased oxidative metabolism of E2F1−/− PCs is mediated by 
reduced PDK4/2 expression, we transduced control-mCherry lentivirus in WT and E2F1−/− 
BM PCs and PDK4-mCherry lentivirus into E2F1−/− BM PCs, and 72 h later, FACS-sorted 
the transduced cells by mCherry expression (Online Figure XI). PDK4 overexpression 
reversed the increase in OCR (at baseline and with FCCP treatment) (Figure 2E & 2F) and 
the decrease in ECAR (at baseline and with Oligomycin treatment) (Figure 2G & 2H) 
observed in the E2F1−/− BM PCs. These results suggest that the increased mtOP in E2F1−/− 
BM PCs is likely the result of PDK4/2 reduction. Notably, in the endothelial differentiation 
assay PDK4 overexpression also significantly reduced the number of CD31+ and Flk-1+ 
E2F1−/− cells and abrogated the difference between E2F1−/− and WT cells (Figure 3A & 
3B).
E2F1 deficiency increases the proportion of PC-derived ECs incorporated in the ischemic 
myocardium
Because the differentiation of recruited BM PCs into endothelial-lineage cells is crucial for 
de novo vasculogenesis, we evaluated whether E2F1 influences the contribution of BM PCs 
to vascular growth. The control-mCherry or PDK4-mCherry transduced WT or E2F1−/− PCs 
were i.v. injected into WT mice immediately after surgical-induction of MI, and 7d later, the 
cells that differentiated into endothelial lineage were assessed by double positive for 
mCherry expression and CD31 staining. In the infarct border zone (i.e., ischemic and 
ischemic reperfusion area), while the total numbers of recruited mCherry+ cells were similar 
(Online Figure XII), the proportion of ECs derived from control-mCherry–transduced 
E2F1−/− PCs was 3 times greater than ECs derived from control-mCherry–transduced WT 
PCs (Figure 3C & 3D). Notably, the proportion of ECs derived from PDK4-mCherry–
transduced E2F1−/− PCs were markedly lower than ECs from control-mCherry–transduced 
E2F1−/− PCs (Figure 3C & 3D). Collectively, the results from our in vivo and in vitro 
experiments suggest that endogenous E2F1 expression impedes the differentiation of BM 
PCs into endothelial-lineage cells in a PDK-dependent manner.
Ablation of E2F1 in BM PCs enhances vascular growth, reduces infarct size, and improves 
cardiac function after MI
To determine the role of E2F1 in BM PC-mediated cardiac repair, we isolated BM 
mononuclear cells (MNCs) from E2F1−/−eGFP and WTeGFP mice and transplanted 
(separately) into lethally irradiated WT mice; 8 weeks later, we surgically induced 
myocardial infarction (MI) in the recipients with a BM engraftment over 90% (Online 
Figure XIII). On day 28 post-MI, left-ventricular (LV) fraction shortening (FS) and ejection 
fraction (EF) were significantly greater (Figure 4A & 4B) and infarct size was significantly 
smaller (Figure 4C & 4D) in mice with E2F1−/−eGFP BM than in mice with WTeGFP BM. 
To assess endothelial differentiation and angiogenesis of BM PCs in the ischemic 
myocardium, MI mice were perfused with lectin-Rhodamine to identify function vessels. At 
the ischemic region, the proportion of GFP+ cells that also incorporated the lectin stain was 
significantly greater in mice with E2F1−/−eGFP BM than in mice with WTeGFP BM, which 
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suggests that E2F1 deficiency promotes the differentiation of BM cells into ECs (Figure 4E 
& 4F). In addition, mice with E2F1−/−eGFP BM demonstrated a significantly higher 
capillary density than mice with WTeGFP BM. Collectively, these results suggest that 
ablation of E2F1 enhances BM PC-mediated ischemic cardiac repair.
DISCUSSION
In this study, we have identified a novel mechanism by which E2F1, a transcription factor 
and classic cell-cycle regulator, suppresses BM PC oxidative metabolism and endothelial 
differentiation through expression of the glycolysis enzymes PDK4/2 (Figure 5). Compared 
to WT BM PCs, E2F1−/− BM PCs express less PDK4/2, consume more oxygen, and 
differentiate more readily into endothelial-lineage cells; and all these effects can be reversed 
by PDK4 overexpression. Remarkably, replacement of WT BM with E2F1−/− BM in mice 
significantly increases the contribution of BM PCs to new vessel formation, reduces infarct 
size, and improves cardiac function after MI. Thus, E2F1-mediated metabolic control 
impedes adult BM PCs from responding to angiogenic cues in the ischemic myocardial 
tissue. The experiments described in this report comprise the first investigation of the 
relationship between the metabolic state and endothelial differentiation in BM PCs. Our 
results are consistent with recent reports, suggesting that metabolism can critically 
determine the stem cell fate 9, 24, and that modulation of BM PC metabolism may hold 
promise for enhancing the effectiveness of cardiovascular cell therapy.
The significance of E2F1 and PDK4/2 in ischemic heart disease has been increasingly 
recognized in last several years 25. E2F1 is upregulated in ischemic human hearts 26, and 
infarct sizes are remarkably reduced when E2F1 is genetically deleted in murine models of 
MI 17 and myocardial ischemia reperfusion injury 15. PDK4/2 are also crucially involved in 
the pathogenesis of ischemic cardiac injury, and strategies that target PDK4/2 have recently 
been proposed for the treatment of diabetes and diabetic cardiomyopathy 27–29. Thus, both 
E2F1 and PDK4/2 are deregulated in patients with ischemic heart disease and diabetes, and 
our findings suggest that E2F1–PDK4/2 may be an important metabolic pathway in BM PCs 
that underlies the functional impairment of EPCs in these patients 30. This new 
understanding have implications not just for cell therapy, but also for enhancing the 
reparative potential of patients’ endogenous PC population.
Recently Blanchet et al have shown that E2F1 deficiency results in an elevated mtOP in 
skeletal muscle and brown adipose tissues via upregulating genes in the mitochondrial 
respiratory chain 18. In this current study, we confirmed that mtOP is also elevated in the 
E2F1−/− BM PCs; but intriguingly, this is mediated by reduced PDK4/2 expression, which 
highlights the tissue-specificity of E2F1 targets. Given the largely overlapping 
phosphorylation sites on PDH between PDK4 and PDK2 11, it is not surprising that 
overexpressing PDK4 alone can reverse the effect of both PDK4 and PDK2 downregulation.
Intriguingly, a downregulation of PDK4/PDK2 in E2F1−/− PCs did not alter the baseline 
hematopoietic lineage differentiation in the BM, as evidenced by our hematopoietic lineage 
analyses and BM transplantation assays. However, it should be noted that a complete 
deletion of both PDK4 and PDK2 indeed enhances hematopoietic lineage differentiation9. 
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Thus, the degrees of PDK4/PDK2 downregulation needed for endothelial differentiation 
under angiogenic stress and for hematopoietic lineage differentiation in the BM are different. 
These observations highlight the difference in the cellular programs of these two 
developmentally-related but functionally-distinct cell types. In addition, the site of ischemic 
injury and the BM stem-cell niche are distinct microenvironments 31, and it is possible that 
the cellular effect of E2F1-deficiency is differentially counteracted by their environmental 
signals; this hypothesis however is beyond the scope of this current study and remains a 
subject of our future investigations.
In addition, we and others have previously shown that loss of E2F1 in mice protects limb 
and cardiac tissues from ischemic and ischemic reperfusion injuries via increased expression 
of angiogenic factors (including VEGF) and reduced apoptosis, respectively 15–17. Thus it is 
likely that both VEGF upregulation (paracrine effect) and PDK2/4 downregulation 
(autonomous effect) contribute to the enhanced neovascularization in E2F1−/− animals. 
However, it should be noted that the exaggerated VEGF upregulation in E2F1−/− mice 
occurs primarily during ischemic insults, neither a high vascularity nor perturbation of bone 
marrow niche was observed in these animals 16 (Online Figure XIV). More importantly, 
E2F1−/− BM PCs display a significantly greater differentiation capacity in a “super-
physiological” concentration of VEGF (i.e., much higher than the level of VEGF secreted 
from cells) in our differentiation assays, which suggests that the E2F1/PDK4-mediated 
control of PC differentiation is likely independent of VEGF effect.
Relative to many other cell types, vascular ECs display a higher rate of glycolysis and lower 
rate of mitochondrial respiration, and increased glycolysis driven by PFKFB3 
overexpression in ECs enhances vessel sprouting and tip cell function 32. These 
observations, although fascinating, should not detract the regulatory role of mitochondrial 
respiration, which has been associated with the differentiation of various stem/progenitor 
cells 33. Importantly, it is still unclear how glycolysis flux affects tip cell function and what 
intermediate metabolites are involved in the regulation. Conceivably, tip cells and EPCs have 
different cellular environment; and sprouting and differentiation have different energy 
demands and require different metabolites-induced signaling pathways.
E2F1 is a classic regulator of cell-cycle progression and apoptosis 34. However, unlike in 
cancer cells, deletion of E2F1 in BM PCs does not affect proliferation or apoptosis. These 
results are consistent with our previous observations in ECs that E2F1 is dispensable for EC 
proliferation and apoptosis while E2F3 is essential for EC growth and angiogenesis 16, 17, 35. 
These observations highlight the cell-type dependent actions of E2F family of transcription 
factors in the cardiovascular system.
Although our data have clearly established the role of E2F1 and the E2F1–PDK4/2 pathway 
in PC oxidative metabolism and endothelial differentiation, specific metabolites are yet to be 
identified. Multiple metabolic changes downstream of PDK/PDH, including the metabolic 
intermediates of mtOP, may potentially contribute to the regulation of PC differentiation and 
modification of cell phenotype. Emerging evidence now suggests that metabolites can 
regulate cell function by acting as cofactors or substrates for key enzymes of epigenetic 
modifications. For example, Acetyl-CoA, the fuel of TCA cycle, is a substrate used by 
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histone acetyltransferase enzymes to modify histone tails of chromatins in eukaryotic cells 
36
, and nicotinamide adenine dinucleotide (NAD), a key electron carrier of mtOP, is 
consumed by the class III histone deacetylases as a cofactor 37. In addition, the metabolic 
changes can alter epigenetic modifications by changing the concentration of those substrates, 
which eventually lead to phenotype modifications of cells 38. Furthermore, other products 
and enzymes associated with mtOP, like ROS 39 (Online Figure XV) and ATP synthase 40, 
may also contribute to the PC differentiation. Importantly, the enhancement of 
differentiation of E2F1−/− BM PCs might not be limited to endothelial-lineage; thus a 
thorough analysis of potential PC differentiation to other lineage cells are warranted.
In conclusion, our results suggest that the E2F1–PDK4/2 pathway critically controls 
oxidative metabolism and endothelial differentiation in BM PCs and may be a novel 
therapeutic target for enhancing the effectiveness of cell therapy for ischemic heart disease.
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Nonstandard Abbreviations and Acronyms
BM bone marrow
ECAR extracellular acidification rate
GFP green fluorescent protein
HSC hematopoietic stem cells
IF immunofluorescence
IL interleukin
LAD left anterior descending
LVEF left ventricular ejection fraction
LVFS left ventricular fractional shortening
LVEDV left ventricular end-diastolic volume
LVESV left ventricular end-systolic volume
Xu et al. Page 11
Circ Res. Author manuscript; available in PMC 2019 March 02.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
MI myocardial infarction
MNC mononuclear cell
mtOP mitochondrial oxidative phosphorylation
OCR oxygen consumption rate
PC progenitor cell
PPP pentose phosphate pathway
qPCR quantitative polymerase chain reaction
TCA tricarboxylic acid
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NOVELTY AND SIGNIFICANCE
What Is Known?
• Adult bone marrow progenitor cells (BM PCs) have differentiation potential 
into endothelial cell lineage; however, little evidence suggests their de novo 
vasculogenesis in the ischemic tissue.
• The efficacy of cell therapy is modest and attributed to paracrine mechanisms.
• Deletion or inhibition of E2F1 is protective of ischemic injury.
• The differentiation of stem/progenitor cells is associated with an increase in 
oxidative metabolism.
What New Information Does This Article Contribute?
• Deletion of E2F1 in BM PCs augments oxidative metabolism, which 
promotes endothelial differentiation.
• E2F1 suppresses oxidative metabolism by increasing pyruvate dehydrogenase 
kinase 4 (PDK4) and PDK2 expression.
• Deletion of E2F1 in BM enhances PC-mediated vasculogenesis and cardiac 
repair after myocardial infarction.
• Modulation of E2F1–PDK4/2 pathway or oxidative metabolism in BM PCs 
may enhance the effectiveness of cell therapy.
Clinical outcomes of cell therapy for ischemic heart disease have been unsatisfactory thus 
far. One of the major barriers to success is that the capacity of de novo vasculogenesis of 
PCs has not been realized, as limited number of BM PCs actually become vascular 
endothelial cells and incorporated into the vessels. In this study, we found that deletion of 
the E2F1 transcription factor in BM PCs enhances endothelial differentiation by 
increased oxidative metabolism, and that E2F1 suppresses oxidative metabolism by 
increasing PDK4 and PDK2 expression. Deletion of E2F1 in the BM enhances PC-
mediated vasculogenesis in the infarcted myocardium and improves the cardiac repair 
and functional recovery. Our findings suggest that the E2F1–PDK4/2 pathway, or 
oxidative metabolism in general, may serve as a novel target for improving the 
effectiveness of cardiovascular cell therapy.
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Figure 1. E2F1−/− BM PCs display an increased OCR, decreased ECAR, and enhanced 
differentiation into endothelial-lineage cells
(A) OCR of freshly-isolated WT and E2F1−− BM PCs at basal condition and in response to 
treatments with Oligomycin (2.5 uM), FCCP (10 uM), and Rotenone (2 uM) plus Antimycin 
(2 uM). n = 5 per group. (B) Quantification of OCR at basal condition (left panel) and after 
FCCP treatment (right panel). n = 5 per group. (C–D) ECAR measurements (C) and 
quantification (D) in WT and E2F1−/− BM PCs at basal condition and after Oligomycin 
treatment. n = 5 per group. (E–F) Flow cytometry analyses (E) and quantification (F) of 
CD31 and Flk-1 expression in WT and E2F1−/− BM PCs after differentiation culture with or 
without Oligomycin for 7d. n = 5 per group.
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Figure 2. E2F1 suppresses BM PC oxidative metabolism via PDK4/2 expression
(A–B) qRT-PCR analyses for mRNA expression of representative glycolysis and 
mitochondrial genes (A) and PDK genes (B) in WT and E2F1−/− BM PCs. The expression 
levels of individual genes were normalized to the β-actin mRNA and expressed relative to 
their levels in WT cells. n = 5 per group. (C–D) Western-blotting analyses (C) and 
quantification (D) of PDK2, PDK4 and phospho-PDH protein levels in BM PCs. n = 4 per 
group. (E–F) OCR measurements (E) and quantification (F, left panel, at basal condition; 
right panel, after FCCP injection) in WT and E2F1−/− PCs transduced with control-mCherry 
lentivirus and in E2F1−/− PCs transduced with PDK4-mCherry lentivirus. n = 5 per group. 
(G–H) ECAR measurements (G) and quantification (H, left panel, at basal condition; right 
panel, after Oligomycin treatment) in WT and E2F1−/− PCs transduced with control-
mCherry lentivirus and in E2F1−/− PCs transduced with PDK4-mCherry lentivirus. n = 5 per 
group.
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Figure 3. Ablation of E2F1 enhances endothelial differentiation of BM PCs via downregulation 
of PDK4/2
WT and E2F1−/− PCs were infected with control-mCherry lentivirus or PDK4-mCherry 
lentivirus and 3d later, sorted for the transduced cells based on mCherry expression by 
FACS. (A–B) The sorted PCs were cultured in EPC differentiation medium for 7d, then 
analyzed by flow cytometry for CD31 and Flk-1 expression (A, representative; B, 
quantification). n = 4 per group. (C–D) The sorted PCs were i.v. injected to WT mice 
immediately after surgical induction of MI; 7d later, the mice were euthanized and the 
cardiac tissues were stained for CD31 (green) to identify the ECs derived from the injected 
PCs (red) (C, representative; D, quantification). n = 8 per group.
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Figure 4. Ablation of E2F1 in BM PCs improves PC-mediated cardiac repair
BMT was performed using E2F1−/−eGFP or eGFP mouse BM to reconstitute WT mouse 
BM, and 8 weeks later, MI was induced surgically in the recipient mice with an engraftment 
over 90%, followed by serial assessments. (A–B) Echocardiography was performed at 
various time points post-MI to evaluate cardiac function, left ventricular (LV) fraction 
shortening (A) and ejection fraction (B). n = 10 per group, **P <0.01 vs. WT. (C–D) 
Representative Masson’s Trichrome staining (c) and quantification of infarct size (D) at 4 
weeks post-MI. The infarct size is expressed as the percentage of the length of fibrotic area 
to the length of the LV inner circumference. n = 10 per group. Scale bar, 1mm. (E–G) After 
last non-invasive physiological measurements at 4 weeks post-MI, the mice were perfused 
with Lectin-Rhodamine and euthanized. (E) Representative immunofluorescent images of 
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the ischemic myocardium at the infarct border zone. Arrow: BM-derived ECs double 
positive for eGFP and Rhodamine showing yellow. (F) The percentage of GFP and lectin 
double positive cells in periinfarct myocardium 4 weeks after MI. n = 10 per group. (G) 
Capillary density in periinfarct myocardium 4 weeks post-MI. n = 10 per group.
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Figure 5. E2F1 suppresses BM PC mtOP and endothelial differentiation
(Left panel) In BM PCs, E2F1 promotes PDK4 and PDK2 expression, which in turn repress 
PDH activity and mtOP to favor anaerobic metabolism, permitting BM PC maintenance and 
stemness. (Right panel) Deletion or inhibition of E2F1 reduces PDK4 and PDK2 expression, 
which de-repress PDH activity and result in a metabolic switch to mtOP, promoting BM PC 
differentiation into vascular endothelial cells that contribute to the ischemic tissue repair.
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